Anxiolytic Compounds: Perspectives in Drug Development - Couverture rigide

Cutler, Neal R.; Sramek, John J.; Kurtz, Neil M.

 
9780471957133: Anxiolytic Compounds: Perspectives in Drug Development
Couverture rigide
ISBN 10 : 0471957135 ISBN 13 : 9780471957133
Editeur : John Wiley & Sons Ltd, 1996

Synopsis

In the exciting and rapidly expanding field of drug development, there is an emphasis on the clear delineation of psychiatric symptoms, syndromes and disorders, and disorders, and improved strategies for making diagnoses. Here the authors concentrate on the anxiolytics, a group of drugs which must be evaluated in carefully defined groups of patients using sensitive outcome measures. Efficacy is not always easy to establish and large clinical trials are needed to verify effectiveness of the drug, the degree of efficacy and the risks of unwanted effects. Conducting these trials is not an easy matter and this timely, critical and comprehensive guide aims to provide awareness of the major issues surrounding development of anxiolytics and, in particular, details of the techniques needed to assess new and hopefully improved therapies. This book, written by authors well known for their extensive experience in the field of drug development, will be of interest to the academic community frequently involved in clinical trials of potential anxiolytic compounds, as well as to the pharmaceutical industry in the formulation of drug development programmes for new anxiolytics.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

Présentation de l'éditeur

In the exciting and rapidly expanding field of drug development, there is an emphasis on the clear delineation of psychiatric symptoms, syndromes and disorders, and disorders, and improved strategies for making diagnoses. Here the authors concentrate on the anxiolytics, a group of drugs which must be evaluated in carefully defined groups of patients using sensitive outcome measures. Efficacy is not always easy to establish and large clinical trials are needed to verify effectiveness of the drug, the degree of efficacy and the risks of unwanted effects. Conducting these trials is not an easy matter and this timely, critical and comprehensive guide aims to provide awareness of the major issues surrounding development of anxiolytics and, in particular, details of the techniques needed to assess new and hopefully improved therapies. This book, written by authors well known for their extensive experience in the field of drug development, will be of interest to the academic community frequently involved in clinical trials of potential anxiolytic compounds, as well as to the pharmaceutical industry in the formulation of drug development programmes for new anxiolytics.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Éditeur
John Wiley & Sons Ltd
Date d'édition
1996
Langue
anglais
ISBN 10 
0471957135
ISBN 13 
9780471957133
Reliure
Relié
Nombre de pages
176
Coordonnées du fabricant
non disponible
Personne responsable
non disponible